The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer
Experts discuss the relevance of PD-L1 CPS in predicting immunotherapy efficacy, other complementary biomarkers, the benefits of adding nivolumab to a FOLFOX regimen, and how the CheckMate 649 trial and its recent 5-year update have influenced the use of nivolumab in combination with chemotherapy for advanced gastric and gastroesophageal adenocarcinomas.
EP: 1.Robert’s Journey With HER2 Upper GI Cancer
EP: 2.Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy
EP: 3.Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment
EP: 4.The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer
Video content above is prompted by the following:
• How relevant is PD-L1 CPS in predicting the efficacy of immunotherapy in this context, and are there other biomarkers that could complement CPS in selecting patients for IO therapies?
• What is the benefit of adding nivolumab to a FOLFOX regimen in this patient, and how does immunotherapy enhance the efficacy of chemotherapy in this setting?
• How has the CheckMate 649 trial influenced the use of nivolumab in combination with chemotherapy for advanced gastric and gastroesophageal adenocarcinomas?
• Please comment on the recently presented 5-year update of CheckMate 649
